Document Detail

Tolerability and steady-state pharmacokinetics of terodiline and its main metabolites in elderly patients with urinary incontinence.
MedLine Citation:
PMID:  2753067     Owner:  NLM     Status:  MEDLINE    
The elderly form an important target group for the treatment of urinary urge incontinence with drugs such as terodiline (Mictrol, Terolin). In order to evaluate its steady-state pharmacokinetics and tolerability in geriatric patients terodiline 12.5 mg b.d. was given to 28 hospitalized patients with urinary incontinence (mean age 85 years) for six weeks. The patients were monitored during the study and for 6 weeks afterwards, blood samples being taken at regular intervals. In addition to these multi-diseased and polymedicated patients, a small, homogenous group of healthy volunteers (mean age 40 years) was studied as a reference group, being given terodiline 12.5 mg b.d. for 2 weeks. Terodiline was generally well tolerated by the patients and no significant change in blood pressure or heart rate were found. One patient was withdrawn due to adverse effects. The mean terminal half-life of terodiline was 131 h and the clearance after oral administration (clearance/systemic availability) was 39 ml.min-1. The corresponding figures for the healthy volunteers were 57 h and 75 ml.min-1. The average steady-state serum concentration was 518 micrograms.l-1 in the geriatric patients and 238 micrograms.l-1 in the healthy volunteers. Steady-state was reached within 3 weeks in 20 of the 28 patients and within 5 weeks in 7 patients. In the geriatric patients the steady-state serum concentration of the main metabolite p-hydroxyterodiline, during the last three weeks on terodiline was 45 micrograms.l-1, 57 micrograms.l-1, and 45 micrograms.l-1, respectively, and a similar value was found in the healthy volunteers, 47 micrograms.l-1.(ABSTRACT TRUNCATED AT 250 WORDS)
B Hallén; S Bogentoft; S Sandquist; S Strömberg; G Setterberg; E Ryd-Kjellén
Related Documents :
15622577 - A prospective, randomized, controlled clinical trial of placement of the artificial bow...
3315777 - Treatment of urgency and urge incontinence with flavoxate in the people's republic of c...
12501047 - Sacral neuromodulation in an older, urge-incontinent population.
18519887 - Evaluation of the treatment tradeoff method in rectal cancer patients: is surgery prefe...
21086347 - Bladder and buccal mucosa graft in urethral stricture reconstruction.
22202547 - Patency rates of microsurgical vasoepididymostomy for patients with idiopathic obstruct...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  36     ISSN:  0031-6970     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  1989  
Date Detail:
Created Date:  1989-09-01     Completed Date:  1989-09-01     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  487-93     Citation Subset:  IM    
Department of Pharmacokinetics and Metabolism, R & D, Kabi, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Blood Pressure / drug effects
Butylamines / adverse effects,  pharmacokinetics*,  pharmacology
Heart Rate / drug effects
Parasympatholytics / adverse effects,  pharmacokinetics*,  pharmacology
Urinary Incontinence / drug therapy*
Reg. No./Substance:
0/Butylamines; 0/Parasympatholytics; 15793-40-5/terodiline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Felodipine reduces the absorption of theophylline in man.
Next Document:  In vitro protein binding of propafenone in normal and uraemic human sera.